Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

NCT ID: NCT02789332

Last Updated: 2020-03-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 107 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-09-30
• Study Completion Date: 2020-02-29

Brief Summary

This is a multicenter, prospective, randomized, open-label phase II study evaluating the efficacy and safety of PO→EC as neoadjuvant treatment of operable and locally advanced breast cancer in patients with HR deficiency. Patients will be randomized to receive

• paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg (4X25mg) twice daily for 12 weeks (65 patients) or
• paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (37 patients) both followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.

The control arm was chosen to allow direct comparison with one of the currently considered standard of care regimen.

Detailed Description

The efficacy of olaparib in germline HRD score high with or without BRCA 1/2 mutation carriers with breast cancer is not well described

• The efficacy and safety of olaparib included in a standard of care regimen like paclitaxel weekly followed by epirubicin and cyclophosphamide (Pw-->EC) is unknown
• Carboplatin increased the pCR rate in patients with triple-negative breast cancer (TNBC) in two randomized phase II neoadjuvant studies when added to an anthracycline, cyclophosphamide and paclitaxel (GeparSixto, CALBG 40603). pCR rates were even higher in patients with germline BRCA 1 or 2 mutations (ypT0/is ypN0 65%) and with HRD score high (ypT0/is ypN0 63%).
• The TNT study showed a doubling in response rate for patients receiving carboplatin vs docetaxel in patients with germline BRCA 1 or 2 mutations.
• There is a high correlation between tumor and germline BRCA 1/2 mutations.
• Data from Geparsixto study showed that triple negative breast patients have an HR deficiency in about 70% (67% have a high HRD and 30% have a tBRCA mutation)
• About 5% of tBRCA patients have a low HRD score
• gBRCA2 patients are older when diagnosed and are more likely to have an HRpos tumor.
• The GeparOLA study aims to support the decision for a phase III study exploring the addition of olaparib to a Pw-->EC schedule by providing an estimate on the pCR rate in the targeted population but also by providing estimate comparison to paclitaxel and carboplatin followed by epirubicin and cyclophosphamide (PCb-->EC) as carboplatin is more and more considered a standard option of care in HR deficient patients (tBRCA 1/2 mutations and/or HRD score high).

Conditions

Breast Cancer; Triple Negative Breast Neoplasms; HRpos Breast Neoplasms; BRCA 1 /2 and / or HRD

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Paclitaxel with Carboplatin (PwCb)

paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (37 patients) followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.

Group Type: ACTIVE_COMPARATOR

PwCb

Intervention Type: DRUG

paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)

EC

Intervention Type: DRUG

both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.

Surgery after neoadjuvant Therapy

Intervention Type: PROCEDURE

In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.

Stratification

Intervention Type: OTHER

Hormone-receptor status (HR+ vs HR-) Age \< 40 years vs \>= 40 years

Paclitaxel with Olaparib (PwO)

paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (65 patients)

followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.

Group Type: EXPERIMENTAL

PwO

Intervention Type: DRUG

paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)

EC

Intervention Type: DRUG

both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.

Surgery after neoadjuvant Therapy

Intervention Type: PROCEDURE

In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.

Stratification

Intervention Type: OTHER

Hormone-receptor status (HR+ vs HR-) Age \< 40 years vs \>= 40 years

Interventions

PwO

paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)

Intervention Type: DRUG

PwCb

paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)

Intervention Type: DRUG

EC

both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.

Intervention Type: DRUG

Surgery after neoadjuvant Therapy

In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.

Intervention Type: PROCEDURE

Stratification

Hormone-receptor status (HR+ vs HR-) Age \< 40 years vs \>= 40 years

Intervention Type: OTHER

Other Intervention Names

Paclitaxel Olaparib over 12 weeks; Paclitaxel Carboplatin over 12 weeks, Control arm currently considered standard of care regimen; Epirubicin 90 mg/m² and Cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks; Randomization will be performed using Pocock minimization method, stratified for the following criteria:

Eligibility Criteria

Inclusion Criteria

1. Written informed consent for all study specific procedures according to local regulatory requirements prior to beginning specific protocol procedures.

2. Complete baseline documentation must be sent to GBG Forschungs GmbH.

3. Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration alone is not sufficient. Incisional biopsy is not allowed. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint.

4. Centrally confirmed negative HER2-status. Centrally confirmed estrogen and progesterone receptor, and Ki-67 status detected on core biopsy. ER/PR positive is defined as ≥1% stained cells and HER2-positive is defined as IHC 3+ or in-situ hybridisation (ISH) ratio ≥2.0. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has therefore to be sent to the Dept. of Pathology at the Charité, Berlin prior to randomization.

5. Centrally confirmed tumor Homologous Recombinant Deficiency score (tBRCA positive/mutated and/or HRD high). Patients with known gBRCA and/or tBRCA status can be enrolled prior to the central test results available.

6. Tumor lesion in the breast with a palpable size of > 2 cm or a sonographical size of >1 cm in maximum diameter. If the tumor is not detectable with sonography mammography assessment can be considered. The lesion has to be measurable in two dimensions, preferably by sonography. In case of inflammatory disease, the extent of inflammation can be used as measurable lesion.

7. Patients must be in the following stages of disease:

• cT2 - cT4a-d or
• cT1c and cN+ or cT1c and pNSLN+ or
• cT1c and ER-neg and PR-neg or
• cT1c and Ki67>20% In patients with multifocal or multicentric breast cancer, the largest lesion should be measured and at least one lesion has to meet the above criteria

8. Age > 18 years.

9. Karnofsky Performance status index ≥ 80%.

10. Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or shortening fraction) within 3 months prior to randomization. Results must be above the normal limit of the institution.

11. Laboratory requirements:

Hematology

• Absolute neutrophil count (ANC) ≥2.0 x 109 / L and
• Platelets ≥100 x 109 / L and
• Hemoglobin ≥10 g/dL (≥ 6.2 mmol/L) Hepatic function
• Total bilirubin ≥1.5x UNL and
• ASAT (SGOT) and ALAT (SGPT) ≥1.5x UNL and
• Alkaline phosphatase ≥2.5x UNL.

12. Negative pregnancy test (urine or serum) within 14 days prior to randomization for all women of childbearing potential.

13. Complete staging work-up within 3 months prior to randomization. All patients must have bilateral mammography, breast ultrasound (≥21 days, and in no case exceed 6 weeks prior to randomization) (Note MRI/ CT scan may be used as an alternative imaging technique). In case of high risk according to guidelines: chest X-ray (PA and lateral) or as an alternative breast MRI/CT, abdominal ultrasound or CT scan or MRI, and bone scan in case of high risk for primary metastasis according to guidelines. In case of positive bone scan, bone X-ray or CT scan is mandatory. Other tests may be performed as clinically indicated.

14. Male or female patients

15. Patients must be available and compliant for central diagnostics, treatment and follow-up.

Exclusion Criteria

1. Prior chemotherapy for any malignancy within 5 years.

2. Prior radiation therapy for breast cancer within 5 years.

3. Pregnant or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization) during study treatment.

4. Inadequate general condition (not fit for anthracycline-taxane-targeted agents-based chemotherapy).

5. Previous malignant disease without being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer).

6. Known or suspected congestive heart failure (>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP >140 / 90 mm Hg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.

7. History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent.

8. Patients currently in an institution by order of jurisdictional or governmental grounds.

9. Currently active infection.

10. Definite contraindications for the use of corticosteroids.

11. Known hypersensitivity reaction to one of the compounds or incorporated substances used in this protocol.

12. Concurrent treatment with:

• chronic corticosteroids unless initiated > 6 months prior to study entry and at low dose (10 mg or less methylprednisolone or equivalent).
• sex hormones. Prior treatment must be stopped before study entry.
• other experimental drugs or any other anti-cancer therapy.

13. Participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry.

14. Prior use of a PARP-Inhibitor

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

GBG Forschungs GmbH

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sibylle 0 Loibl, Prof., MD

Role: STUDY_CHAIR

Sibylle Loibl, Prof., MD ASCO, ESGO, ESMO, DKG, DGGG, AGO, DGS, BIG, BCIRG, St. Gallen Faculty Member, SABCS Faculty member

Locations

Kliniken Esslingen, Gynäkologie Onkologie

Esslingen am Neckar, Baden-Wurttemberg, Germany

Universitätsklinikum Erlangen

Erlangen, Bavaria, Germany

Onkologisches Zentrum am Rotkreuzklinikum München

München, Bavaria, Germany

Elisabeth Krankenhaus

Kassel, Hesse, Germany

Sana Klinikum Hameln-Pyrmont

Hamelin, Lower Saxony, Germany

Gemeinschaftspraxis

Hildesheim, Lower Saxony, Germany

Klinikum Südstadt

Rostock, Mecklenburg-Vorpommern, Germany

Marienhospital Witten

Witten, North Rhine-Westphalia, Germany

Martin-Luther-Universität Halle Wittenberg

Halle, Saxony-Anhalt, Germany

Johanniter-Krankenhaus Genthin-Stendal

Stendal, Saxony-Anhalt, Germany

SRH Wald-Klinikum Gera GmbH

Gera, Thuringia, Germany

Praxisklinik

Berlin, , Germany

Countries

Germany

References

Von Minckwitz G, Timms K, Untch M, Elkin E P, Fasching P A, Schneeweiss A et al. Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. J Clin Oncol 33, 2015 (suppl; abstr 1004)

Reference Type: BACKGROUND

Tutt A, Ellis P, Kilburn L et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. SABCS 2014.

Reference Type: BACKGROUND

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4.

Reference Type: BACKGROUND

PMID: 25092775 (View on PubMed)

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kummel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30.

Reference Type: BACKGROUND

PMID: 24794243 (View on PubMed)

DOI: 10.1200/JCO.2019.37.15_suppl.506 Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 506-506. Fasching PA, Jackisch J, Rhiem K et al. GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). J Clin Oncol 2019; 37.15_suppl.506; oral presentation

Reference Type: RESULT

Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler RK, Hahnen E, Untch M, Burchardi N, Blohmer JU, Loibl S; German Breast Group and Arbeitsgemeinschaft Gynakologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2021 Jan;32(1):49-57. doi: 10.1016/j.annonc.2020.10.471. Epub 2020 Oct 21.

Reference Type: DERIVED

PMID: 33098995 (View on PubMed)

Related Links

http://www.gbg.de/de/studien/aktive-studien.php

GeparOla website

Other Identifiers

GBG90

Identifier Type: -

Identifier Source: org_study_id